Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 4/2006

Open Access 01-08-2006 | Research article

Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence

Authors: Laurent G Ameye, Winnie SS Chee

Published in: Arthritis Research & Therapy | Issue 4/2006

Login to get access

Abstract

The scientific and medical community remains skeptical regarding the efficacy of nutrition for osteoarthritis despite their broad acceptation by patients. In this context, this paper systematically reviews human clinical trials evaluating the effects of nutritional compounds on osteoarthritis. We searched the Medline, Embase, and Biosis databases from their inception to September 2005 using the terms random, double-blind method, trial, study, placebo, and osteoarthritis. We selected all peer-reviewed articles reporting the results of randomised human clinical trials (RCTs) in osteoarthritis that investigated the effects of oral interventions based on natural molecules. Studies on glucosamine and chondroitin sulfate were excluded. The quality of the RCTs was assessed with an osteoarthritic-specific standardised set of 12 criteria and a validated instrument. A best-evidence synthesis was used to categorise the scientific evidence behind each nutritional compound as good, moderate, or limited. A summary of the most relevant in vitro and animal studies is used to shed light on the potential mechanisms of action. Inclusion criteria were met by 53 RCTs out of the 2,026 identified studies. Good evidence was found for avocado soybean unsaponifiables. Moderate evidence was found for methylsulfonylmethane and SKI306X, a cocktail of plant extracts. Limited evidence was found for the Chinese plant extract Duhuo Jisheng Wan, cetyl myristoleate, lipids from green-lipped mussels, and plant extracts from Harpagophytum procumbens. Overall, scientific evidence exists for some specific nutritional interventions to provide symptom relief to osteoarthritic patients. It remains to be investigated whether nutritional compounds can have structure-modifying effects.
Literature
1.
Yelin E: The economics of osteoarthritis. Osteoarthritis. Edited by: Brandt KD, Doherty M, Lohmander LS. 2003, Oxford: Oxford University Press, 17-21.
2.
Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, et al: EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003, 62: 1145-1155. 10.1136/ard.2003.011742.PubMedCentralPubMed
3.
Abramson SB: The role of NSAIDs in the treatment of osteoarthritis. Osteoarthritis. Edited by: Brandt KD, Doherty M, Lohmander LS. 2003, Oxford: Oxford University Press, 251-258.
4.
German B, Schiffrin EJ, Reniero R, Mollet B, Pfeifer A, Neeser JR: The development of functional foods: lessons from the gut. Trends Biotechnol. 1999, 17: 492-499. 10.1016/S0167-7799(99)01380-3.PubMed
5.
Kalra EK: Nutraceutical – definition and introduction. AAPS PharmSci. 2003, 5: E25-10.1208/ps050325.PubMed
6.
Zeisel SH: Regulation of "nutraceuticals". Science. 1999, 285: 1853-1855. 10.1126/science.285.5435.1853.PubMed
7.
Halsted CH: Dietary supplements and functional foods: 2 sides of a coin?. Am J Clin Nutr. 2003, 77: 1001S-1007S.PubMed
8.
Roberfroid MB: Defining functional foods. Functional Foods. Concept to Product. Edited by: Gibson GR, Williams CM. 2000, Boca Raton: CRC Press, 1-18.
9.
Diplock AT, Aggett PJ, Ashwell M, Bornet F, Fern FB, Roberfroid MB: Scientific concepts of functional foods in Europe: consensus document. Br J Nutr. 1999, 81 (Suppl 1): S1-S27.
10.
Roberfroid MB: Concepts and strategy of functional food science: the European perspective. Am J Clin Nutr. 2000, 71: 1660S-1664S.PubMed
11.
Ramsey SD, Spencer AC, Topolski TD, Belza B, Patrick DL: Use of alternative therapies by older adults with osteoarthritis. Arthritis Rheum. 2001, 45: 222-227. 10.1002/1529-0131(200106)45:3<222::AID-ART252>3.0.CO;2-N.PubMed
12.
Bottiglieri T: S-Adenosyl-L-methionine (SAMe): from the bench to bedside – molecular basis of a pleitropic molecule. Am J Clin Nutr. 2002, 76: 1151S-1157S.PubMed
13.
Leeb BF, Schweitzer H, Montag K, Smolen JS: A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol. 2000, 27: 205-211.PubMed
14.
McAlindon TE, LaValley MP, Gulin JP, Felson DT: Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 2000, 283: 1469-1475. 10.1001/jama.283.11.1469.PubMed
15.
Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY: Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med. 2003, 163: 1514-1522. 10.1001/archinte.163.13.1514.PubMed
16.
Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, Hochberg MC, Wells G: Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005, CD002946-2
17.
Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000, 43: 1905-1915. 10.1002/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P.
18.
19.
Altman R, Brandt K, Hochberg M, Moskowitz R, Bellamy N, Bloch DA, Buckwalter J, Dougados M, Ehrlich G, Lequesne M, et al: Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthritis Cartilage. 1996, 4: 217-243. 10.1016/S1063-4584(05)80101-3.PubMed
20.
Recommendations for the registration of drugs used in the treatment of osteoarthritis. Group for the respect of ethics and excellence in science (GREES): osteoarthritis section. Ann Rheum Dis. 1996, 55: 552-557.
21.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996, 17: 1-12. 10.1016/0197-2456(95)00134-4.PubMed
22.
Schilter B, Andersson C, Anton R, Constable A, Kleiner J, O'Brien J, Renwick AG, Korver O, Smit F, Walker R, et al: Guidance for the safety assessment of botanicals and botanical preparations for use in food and food supplements. Food Chem Toxicol. 2003, 41: 1625-1649. 10.1016/S0278-6915(03)00221-7.PubMed
23.
Henrotin YE, Labasse AH, Jaspar JM, De Groote DD, Zheng SX, Guillou GB, Reginster JY: Effects of three avocado/soybean unsaponifiable mixtures on metalloproteinases, cytokines and prostaglandin E2 production by human articular chondrocytes. Clin Rheumatol. 1998, 17: 31-39. 10.1007/BF01450955.PubMed
24.
Blotman F, Maheu E, Wulwik A, Caspard H, Lopez A: Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial. Rev Rhum Engl Ed. 1997, 64: 825-834.PubMed
25.
Appelboom T, Schuermans J, Verbruggen G, Henrotin Y, Reginster JY: Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scand J Rheumatol. 2001, 30: 242-247. 10.1080/030097401316909602.PubMed
26.
Maheu E, Mazieres B, Valat JP, Loyau G, Le Loet X, Bourgeois P, Grouin JM, Rozenberg S: Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis Rheum. 1998, 41: 81-91. 10.1002/1529-0131(199801)41:1<81::AID-ART11>3.0.CO;2-9.PubMed
27.
Lequesne M, Maheu E, Cadet C, Dreiser RL: Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Rheum. 2002, 47: 50-58. 10.1002/art1.10239.PubMed
28.
Ernst E: Avocado-soybean unsaponifiables (ASU) for osteoarthritis – a systematic review. Clin Rheumatol. 2003, 22: 285-288. 10.1007/s10067-003-0731-4.PubMed
29.
Cake MA, Read RA, Guillou B, Ghosh P: Modification of articular cartilage and subchondral bone pathology in an ovine meniscectomy model of osteoarthritis by avocado and soya unsaponifiables (ASU). Osteoarthritis Cartilage. 2000, 8: 404-411. 10.1053/joca.1999.0315.PubMed
30.
Mauviel A, Daireaux M, Hartmann DJ, Galera P, Loyau G, Pujol JP: Effects of unsaponifiable extracts of avocado/soy beans (PIAS) on the production of collagen by cultures of synoviocytes, articular chondrocytes and skin fibroblasts. Rev Rhum Mal Osteoartic. 1989, 56: 207-211.PubMed
31.
Mauviel A, Loyau G, Pujol JP: Effect of unsaponifiable extracts of avocado and soybean (Piascledine) on the collagenolytic action of cultures of human rheumatoid synoviocytes and rabbit articular chondrocytes treated with interleukin-1. Rev Rhum Mal Osteoartic. 1991, 58: 241-245.PubMed
32.
Henrotin YE, Sanchez C, Deberg MA, Piccardi N, Guillou GB, Msika P, Reginster JY: Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes. J Rheumatol. 2003, 30: 1825-1834.PubMed
33.
Boumediene K, Felisaz N, Bogdanowicz P, Galera P, Guillou GB, Pujol JP: Avocado/soya unsaponifiables enhance the expression of transforming growth factor beta1 and beta2 in cultured articular chondrocytes. Arthritis Rheum. 1999, 42: 148-156. 10.1002/1529-0131(199901)42:1<148::AID-ANR18>3.0.CO;2-U.PubMed
34.
Darlington LG, Stone TW: Antioxidants and fatty acids in the amelioration of rheumatoid arthritis and related disorders. Br J Nutr. 2001, 85: 251-269.PubMed
35.
Calder PC: n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci (Lond). 2004, 107: 1-11.
36.
Stammers T, Sibbald B, Freeling P: Efficacy of cod liver oil as an adjunct to non-steroidal anti-inflammatory drug treatment in the management of osteoarthritis in general practice. Ann Rheum Dis. 1992, 51: 128-129.PubMedCentralPubMed
37.
Lippiello L, Walsh T, Fienhold M: The association of lipid abnormalities with tissue pathology in human osteoarthritic articular cartilage. Metabolism. 1991, 40: 571-576. 10.1016/0026-0495(91)90046-Y.PubMed
38.
Lippiello L, Fienhold M, Grandjean C: Metabolic and ultrastructural changes in articular cartilage of rats fed dietary supplements of omega-3 fatty acids. Arthritis Rheum. 1990, 33: 1029-1036.PubMed
39.
Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN: Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med. 2005, 201: 713-722. 10.1084/jem.20042031.PubMedCentralPubMed
40.
Curtis CL, Hughes CE, Flannery CR, Little CB, Harwood JL, Caterson B: n-3 fatty acids specifically modulate catabolic factors involved in articular cartilage degradation. J Biol Chem. 2000, 275: 721-724. 10.1074/jbc.275.2.721.PubMed
41.
Curtis CL, Rees SG, Cramp J, Flannery CR, Hughes CE, Little CB, Williams R, Wilson C, Dent CM, Harwood JL, et al: Effects of n-3 fatty acids on cartilage metabolism. Proc Nutr Soc. 2002, 61: 381-389. 10.1079/PNS2002174.PubMed
42.
Curtis CL, Rees SG, Little CB, Flannery CR, Hughes CE, Wilson C, Dent CM, Otterness IG, Harwood JL, Caterson B: Pathologic indicators of degradation and inflammation in human osteoarthritic cartilage are abrogated by exposure to n-3 fatty acids. Arthritis Rheum. 2002, 46: 1544-1553. 10.1002/art.10305.PubMed
43.
Halpern GM: Anti-inflammatory effects of a stabilized lipid extract of Perna canaliculus (Lyprinol). Allerg Immunol (Paris). 2000, 32: 272-278. 10.1159/000028950.
44.
Bui LM, Bierer TL: Influence of green lipped mussels (Perna canaliculus) in alleviating signs of arthritis in dogs. Vet Ther. 2003, 4: 397-407.PubMed
45.
Audeval B, Bouchacourt P: Efficacy of Perna canaliculus green-lipped mussel extract in gonarthrosis: a double-blind placebo-controlled trial. Gazette Médicale. 1986, 93: 111-116.
46.
Gibson RG, Gibson SL, Conway V, Chappell D: Perna canaliculus in the treatment of arthritis. Practitioner. 1980, 224: 955-960.PubMed
47.
Gibson SLM, Gibson RG: The treatment of arthritis with a lipid extract of Perna canaliculus: a randomized trial. Complement Ther Med. 1998, 6: 122-126. 10.1016/S0965-2299(98)80003-4.
48.
Cobb CS, Ernst E: Systematic review of a marine nutriceutical supplement in clinical trials for arthritis: the effectiveness of the New Zealand green-lipped mussel Perna canaliculus. Clin Rheumatol. 2006, 25: 275-284. 10.1007/s10067-005-0001-8.PubMed
49.
Bierer TL, Bui LM: Improvement of arthritic signs in dogs fed green-lipped mussel (Perna canaliculus). J Nutr. 2002, 132: 1634S-1636S.PubMed
50.
Hesslink R, Armstrong D, Nagendran MV, Sreevatsan S, Barathur R: Cetylated fatty acids improve knee function in patients with osteoarthritis. J Rheumatol. 2002, 29: 1708-1712.PubMed
51.
52.
Sowers M, Lachance L: Vitamins and arthritis. The roles of vitamins A, C, D, and E. Rheum Dis Clin North Am. 1999, 25: 315-332. 10.1016/S0889-857X(05)70070-3.PubMed
53.
Henrotin Y, Kurz B, Aigner T: Oxygen and reactive oxygen species in cartilage degradation: friends or foes?. Osteoarthritis Cartilage. 2005, 13: 643-654. 10.1016/j.joca.2005.04.002.PubMed
54.
Tetlow LC, Woolley DE: Expression of vitamin D receptors and matrix metalloproteinases in osteoarthritic cartilage and human articular chondrocytes in vitro. Osteoarthritis Cartilage. 2001, 9: 423-431. 10.1053/joca.2000.0408.PubMed
55.
McAlindon TE, Felson DT, Zhang Y, Hannan MT, Aliabadi P, Weissman B, Rush D, Wilson PW, Jacques P: Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study. Ann Intern Med. 1996, 125: 353-359.PubMed
56.
Lane NE, Gore LR, Cummings SR, Hochberg MC, Scott JC, Williams EN, Nevitt MC: Serum vitamin D levels and incident changes of radiographic hip osteoarthritis: a longitudinal study. Study of Osteoporotic Fractures Research Group. Arthritis Rheum. 1999, 42: 854-860. 10.1002/1529-0131(199905)42:5<854::AID-ANR3>3.0.CO;2-I.PubMed
57.
McAlindon TE, Jacques P, Zhang Y, Hannan MT, Aliabadi P, Weissman B, Rush D, Levy D, Felson DT: Do antioxidant micronutrients protect against the development and progression of knee osteoarthritis?. Arthritis Rheum. 1996, 39: 648-656.PubMed
58.
Jensen NH: [Reduced pain from osteoarthritis in hip joint or knee joint during treatment with calcium ascorbate. A randomized, placebo-controlled cross-over trial in general practice]. Ugeskr Laeger. 2003, 165: 2563-2566.PubMed
59.
Schwartz ER, Oh WH, Leveille CR: Experimentally induced osteoarthritis in guinea pigs: metabolic responses in articular cartilage to developing pathology. Arthritis Rheum. 1981, 24: 1345-1355.PubMed
60.
Schwartz ER: The modulation of osteoarthritic development by vitamins C and E. Int J Vitam Nutr Res Suppl. 1984, 26: 141-146.PubMed
61.
Kraus VB, Huebner JL, Stabler T, Flahiff CM, Setton LA, Fink C, Vilim V, Clark AG: Ascorbic acid increases the severity of spontaneous knee osteoarthritis in a guinea pig model. Arthritis Rheum. 2004, 50: 1822-1831. 10.1002/art.20291.PubMed
62.
Meacock SC, Bodmer JL, Billingham ME: Experimental osteoarthritis in guinea-pigs. J Exp Pathol (Oxford). 1990, 71: 279-293.
63.
Stabler TV, Kraus VB: Ascorbic acid accumulates in cartilage in vivo. Clin Chim Acta. 2003, 334: 157-162. 10.1016/S0009-8981(03)00225-0.PubMed
64.
Clark AG, Rohrbaugh AL, Otterness I, Kraus VB: The effects of ascorbic acid on cartilage metabolism in guinea pig articular cartilage explants. Matrix Biol. 2002, 21: 175-184. 10.1016/S0945-053X(01)00193-7.PubMed
65.
McNulty AL, Stabler TV, Vail TP, McDaniel GE, Kraus VB: Dehydroascorbate transport in human chondrocytes is regulated by hypoxia and is a physiologically relevant source of ascorbic acid in the joint. Arthritis Rheum. 2005, 52: 2676-2685. 10.1002/art.21254.PubMed
66.
Schwartz ER, Adamy L: Effect of ascorbic acid on arylsulfatase activities and sulfated proteoglycan metabolism in chondrocyte cultures. J Clin Invest. 1977, 60: 96-106.PubMedCentralPubMed
67.
Daniel JC, Pauli BU, Kuettner KE: Synthesis of cartilage matrix by mammalian chondrocytes in vitro. III. Effects of ascorbate. J Cell Biol. 1984, 99: 1960-1969. 10.1083/jcb.99.6.1960.PubMed
68.
Sandell LJ, Daniel JC: Effects of ascorbic acid on collagen mRNA levels in short term chondrocyte cultures. Connect Tissue Res. 1988, 17: 11-22.PubMed
69.
Tiku ML, Gupta S, Deshmukh DR: Aggrecan degradation in chondrocytes is mediated by reactive oxygen species and protected by antioxidants. Free Radic Res. 1999, 30: 395-405.PubMed
70.
Verzijl N, DeGroot J, Ben ZC, Brau-Benjamin O, Maroudas A, Bank RA, Mizrahi J, Schalkwijk CG, Thorpe SR, Baynes JW, et al: Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum. 2002, 46: 114-123. 10.1002/1529-0131(200201)46:1<114::AID-ART10025>3.0.CO;2-P.PubMed
71.
Machtey I, Ouaknine L: Tocopherol in osteoarthritis: a controlled pilot study. J Am Geriatr Soc. 1978, 26: 328-330.PubMed
72.
Blankenhorn G: [Clinical effectiveness of Spondyvit (vitamin E) in activated arthroses. A multicenter placebo-controlled double-blind study]. Z Orthop Ihre Grenzgeb. 1986, 124: 340-343.PubMed
73.
Scherak O, Kolarz G, Schodl C, Blankenhorn G: [High dosage vitamin E therapy in patients with activated arthrosis]. Z Rheumatol. 1990, 49: 369-373.PubMed
74.
Brand C, Snaddon J, Bailey M, Cicuttini F: Vitamin E is ineffective for symptomatic relief of knee osteoarthritis: a six month double blind, randomised, placebo controlled study. Ann Rheum Dis. 2001, 60: 946-949. 10.1136/ard.60.10.946.PubMedCentralPubMed
75.
Wluka AE, Stuckey S, Brand C, Cicuttini FM: Supplementary vitamin E does not affect the loss of cartilage volume in knee osteoarthritis: a 2 year double blind randomized placebo controlled study. J Rheumatol. 2002, 29: 2585-2591.PubMed
76.
Tiku ML, Shah R, Allison GT: Evidence linking chondrocyte lipid peroxidation to cartilage matrix protein degradation. Possible role in cartilage aging and the pathogenesis of osteoarthritis. J Biol Chem. 2000, 275: 20069-20076. 10.1074/jbc.M907604199.PubMed
77.
Schwartz ER: Effect of vitamins C and E on sulfated proteoglycan metabolism and sulfatase and phosphatase activities in organ cultures of human cartilage. Calcif Tissue Int. 1979, 28: 201-208. 10.1007/BF02441237.PubMed
78.
Galleron S, Borderie D, Ponteziere C, Lemarechal H, Jambou M, Roch-Arveiller M, Ekindjian OG, Cals MJ: Reactive oxygen species induce apoptosis of synoviocytes in vitro. Alpha-tocopherol provides no protection. Cell Biol Int. 1999, 23: 637-642. 10.1006/cbir.1999.0424.PubMed
79.
Jonas WB, Rapoza CP, Blair WF: The effect of niacinamide on osteoarthritis: a pilot study. Inflamm Res. 1996, 45: 330-334. 10.1007/BF02252945.PubMed
80.
McKenney JM, Proctor JD, Harris S, Chinchili VM: A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA. 1994, 271: 672-677. 10.1001/jama.271.9.672.PubMed
81.
Flynn MA, Irvin W, Krause G: The effect of folate and cobalamin on osteoarthritic hands. J Am Coll Nutr. 1994, 13: 351-356.PubMed
82.
Hill J, Bird HA: Failure of selenium-ace to improve osteoarthritis. Br J Rheumatol. 1990, 29: 211-213.PubMed
83.
Kurz B, Jost B, Schunke M: Dietary vitamins and selenium diminish the development of mechanically induced osteoarthritis and increase the expression of antioxidative enzymes in the knee joint of STR/1N mice. Osteoarthritis Cartilage. 2002, 10: 119-126. 10.1053/joca.2001.0489.PubMed
84.
Helliwell TR, Kelly SA, Walsh HP, Klenerman L, Haines J, Clark R, Roberts NB: Elemental analysis of femoral bone from patients with fractured neck of femur or osteoarthrosis. Bone. 1996, 18: 151-157. 10.1016/8756-3282(95)00440-8.PubMed
85.
86.
Miller MJ, Mehta K, Kunte S, Raut V, Gala J, Dhumale R, Shukla A, Tupalli H, Parikh H, Bobrowski P, et al: Early relief of osteoarthritis symptoms with a natural mineral supplement and a herbomineral combination: a randomized controlled trial [ISRCTN38432711]. J Inflamm (Lond). 2005, 2: 11-
87.
Brien S, Lewith G, Walker A, Hicks SM, Middleton D: Bromelain as a treatment for osteoarthritis: a review of clinical studies. Evid Based Complement Alternat Med. 2004, 1: 251-257. 10.1093/ecam/neh035.PubMedCentralPubMed
88.
Maurer HR: Bromelain: biochemistry, pharmacology and medical use. Cell Mol Life Sci. 2001, 58: 1234-1245. 10.1007/PL00000936.PubMed
89.
Tilwe GH, Beria S, Turakhia NH, Daftary GV, Schiess W: Efficacy and tolerability of oral enzyme therapy as compared to diclofenac in active osteoarthrosis of knee joint: an open randomized controlled clinical trial. J Assoc Physicians India. 2001, 49: 617-621.PubMed
90.
Akhtar NM, Naseer R, Farooqi AZ, Aziz W, Nazir M: Oral enzyme combination versus diclofenac in the treatment of osteoarthritis of the knee – a double-blind prospective randomized study. Clin Rheumatol. 2004, 23: 410-415. 10.1007/s10067-004-0902-y.PubMed
91.
Klein G, Kullich W: Short-term treatment of painful osteoarthritis of the knee with oral enzymes. Clin Drug Invest. 2000, 19: 15-23. 10.2165/00044011-200019010-00003.
92.
Singer F, Oberleitner H: Drug therapy of activated arthrosis. On the effectiveness of an enzyme mixture versus diclofenac. Wien Med Wochenschr. 1996, 146: 55-58.PubMed
93.
Warholm O, Skaar S, Hedman E, Molmen HM, Eik L: The effects of a standardized herbal remedy made from a subtype of Rosa canina in patients with osteoarthritis: a double-blind, randomized, placebo-controlled clinical trial. Curr Ther Res. 2003, 64: 21-31. 10.1016/S0011-393X(03)00004-3.PubMedCentralPubMed
94.
Rein E, Kharazmi A, Winther K: A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis – a double-blind, placebo-controlled, randomised trial. Phytomedicine. 2004, 11: 383-391. 10.1016/j.phymed.2004.01.001.PubMed
95.
Winther K, Apel K, Thamsborg G: A powder made from seeds and shells of a rose-hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial. Scand J Rheumatol. 2005, 34: 302-308. 10.1080/03009740510018624.PubMed
96.
Kharazmi A, Winther K: Rose hip inhibits chemotaxis and chemiluminescence of human peripheral blood neutrophils in vitro and reduces certain inflammatory parameters in vivo. Inflammopharmacology. 1999, 7: 377-386.PubMed
97.
Winther K, Rein E, Kharazmi A: The anti-inflammatory properties of rose-hip. Inflammopharmacology. 1999, 7: 63-68.PubMed
98.
Chrubasik S, Conradt C, Black A: The quality of clinicaltrials with Harpagophytum procumbens. Phytomedicine. 2003, 10: 613-623. 10.1078/094471103322331647.PubMed
99.
Lecomte A, Costa JP: Harpagophytum and osteoarthritis: a double-blind placebo-controlled trial. 37°2 Le Magazine. 1992, 15: 27-30.
100.
Chantre P, Cappelaere A, Leblan D, Guedon D, Vandermander J, Fournie B: Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis. Phytomedicine. 2000, 7: 177-183.PubMed
101.
Leblan D, Chantre P, Fournie B: Harpagophytum procumbens in the treatment of knee and hip osteoarthritis. Four-month results of a prospective, multicenter, double-blind trial versus diacerhein. Joint Bone Spine. 2000, 67: 462-467.PubMed
102.
Gagnier JJ, Chrubasik S, Manheimer E: Harpagophytum procumbens for osteoarthritis and low back pain: a systematic review. BMC Complement Altern Med. 2004, 4: 13-23. 10.1186/1472-6882-4-13.PubMedCentralPubMed
103.
Wegener T, Lupke NP: Treatment of patients with arthrosis of hip or knee with an aqueous extract of devil's claw (Harpagophytum procumbens DC.). Phytother Res. 2003, 17: 1165-1172. 10.1002/ptr.1322.PubMed
104.
Schulze-Tanzil G, Hansen C, Shakibaei M: Effect of a Harpagophytum procumbens DC extract on matrix metalloproteinases in human chondrocytes in vitro. Arzneimittelforschung. 2004, 54: 213-220.PubMed
105.
Sandoval M, Okuhama NN, Zhang XJ, Condezo LA, Lao J, Angeles' FM, Musah RA, Bobrowski P, Miller MJ: Anti-inflammatory and antioxidant activities of cat's claw (Uncaria tomentosa and Uncaria guianensis) are independent of their alkaloid content. Phytomedicine. 2002, 9: 325-337. 10.1078/0944-7113-00117.PubMed
106.
Piscoya J, Rodriguez Z, Bustamante SA, Okuhama NN, Miller MJ, Sandoval M: Efficacy and safety of freeze-dried cat's claw in osteoarthritis of the knee: mechanisms of action of the species Uncaria guianensis. Inflamm Res. 2001, 50: 442-448. 10.1007/PL00000268.PubMed
107.
Jha V, Chugh KS: Nephropathy associated with animal, plant, and chemical toxins in the tropics. Semin Nephrol. 2003, 23: 49-65. 10.1053/snep.2003.50003.PubMed
108.
Schmid B, Ludtke R, Selbmann HK, Kotter I, Tschirdewahn B, Schaffner W, Heide L: Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: randomized placebo-controlled, double blind clinical trial. Phytother Res. 2001, 15: 344-350. 10.1002/ptr.981.PubMed
109.
Biegert C, Wagner I, Ludtke R, Kotter I, Lohmuller C, Gunaydin I, Taxis K, Heide L: Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: results of 2 randomized double-blind controlled trials. J Rheumatol. 2004, 31: 2121-2130.PubMed
110.
Mills SY, Jacoby RK, Chacksfield M, Willoughby M: Effect of a proprietary herbal medicine on the relief of chronic arthritic pain: a double-blind study. Br J Rheumatol. 1996, 35: 874-878.PubMed
111.
Chrubasik S, Kunzel O, Model A, Conradt C, Black A: Treatment of low back pain with a herbal or synthetic anti-rheumatic: a randomized controlled study. Willow bark extract for low back pain. Rheumatology (Oxford). 2001, 40: 1388-1393. 10.1093/rheumatology/40.12.1388.
112.
Wigler I, Grotto I, Caspi D, Yaron M: The effects of Zintona EC (a ginger extract) on symptomatic gonarthritis. Osteoarthritis Cartilage. 2003, 11: 783-789. 10.1016/S1063-4584(03)00169-9.PubMed
113.
Altman RD, Marcussen KC: Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis Rheum. 2001, 44: 2531-2538. 10.1002/1529-0131(200111)44:11<2531::AID-ART433>3.0.CO;2-J.PubMed
114.
Marcus DM, Suarez-Almazor ME: Is there a role for ginger in the treatment of osteoarthritis?. Arthritis Rheum. 2001, 44: 2461-2462. 10.1002/1529-0131(200111)44:11<2461::AID-ART424>3.0.CO;2-H.PubMed
115.
Bliddal H, Rosetzsky A, Schlichting P, Weidner MS, Andersen LA, Ibfelt HH, Christensen K, Jensen ON, Barslev J: A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis Cartilage. 2000, 8: 9-12. 10.1053/joca.1999.0264.PubMed
116.
Shen CL, Hong KJ, Kim SW: Effects of ginger (Zingiber officinale Rosc.) on decreasing the production of inflammatory mediators in sow osteoarthrotic cartilage explants. J Med Food. 2003, 6: 323-328. 10.1089/109662003772519877.PubMed
117.
Frondoza CG, Sohrabi A, Polotsky A, Phan PV, Hungerford DS, Lindmark L: An in vitro screening assay for inhibitors of proinflammatory mediators in herbal extracts using human synoviocyte cultures. In Vitro Cell Dev Biol Anim. 2004, 40: 95-101. 10.1290/1543-706X(2004)040<0095:AIVSAF>2.0.CO;2.PubMed
118.
Innes JF, Fuller CJ, Grover ER, Kelly AL, Burn JF: Randomised, double-blind, placebo-controlled parallel group study of P54FP for the treatment of dogs with osteoarthritis. Vet Rec. 2003, 152: 457-460.PubMed
119.
Ferraz MB, Pereira RB, Iwata NM, Atra E: Tipi. A popular analgesic tea: a double-blind cross-over trial in osteoarthritis. Clin Exp Rheumatol. 1991, 9: 205-206.PubMed
120.
Arjmandi BH, Khalil DA, Lucas EA, Smith BJ, Sinichi N, Hodges SB, Juma S, Munson ME, Payton ME, Tivis RD, et al: Soy protein may alleviate osteoarthritis symptoms. Phytomedicine. 2004, 11: 567-575. 10.1016/j.phymed.2003.11.001.PubMed
121.
Kimmatkar N, Thawani V, Hingorani L, Khiyani R: Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee – a randomized double blind placebo controlled trial. Phytomedicine. 2003, 10: 3-7. 10.1078/094471103321648593.PubMed
122.
Badria FA, El-Farahaty T, Shabana AA, Hawas SA, El-Batoty MF: Boswellia-curcumin preparation for treating knee osteoarthritis. Altern Complement Ther. 2002, 8: 341-348. 10.1089/107628002761574635.
123.
Kulkarni RR, Patki PS, Jog VP, Gandage SG, Patwardhan B: Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled, cross-over study. J Ethnopharmacol. 1991, 33: 91-95. 10.1016/0378-8741(91)90167-C.PubMed
124.
Kim JH, Rhee HI, Jung IH, Ryu K, Jung K, Han CK, Kwak WJ, Cho YB, Joo JH: SKI306X, an oriental herbal mixture, suppresses gastric leukotriene B4 synthesis without causing mucosal injury and the diclofenac-induced gastric lesions. Life Sci. 2005, 77: 1181-1193. 10.1016/j.lfs.2004.11.040.PubMed
125.
Jung YB, Roh KJ, Jung JA, Jung K, Yoo H, Cho YB, Kwak WJ, Kim DK, Kim KH, Han CK: Effect of SKI 306X, a new herbal anti-arthritic agent, in patients with osteoarthritis of the knee: a double-blind placebo controlled study. Am J Chin Med. 2001, 29: 485-491. 10.1142/S0192415X01000502.PubMed
126.
Jung YB, Seong SC, Lee MC, Shin YU, Kim DH, Kim JM, Jung YK, Ahn JH, Seo JG, Park YS, Lee CS, et al: A four-week, randomized, double-blind trial of the efficacy and safety of SKI 306 X: a herbal anti-arthritic agent versus diclofenac in osteoarthritis of the knee. Am J Chinese Medicine. 2004, 32: 291-301. 10.1142/S0192415X04001941.
127.
Choi JH, Choi JH, Kim DY, Yoon JH, Youn HY, Yi JB, Rhee HI, Ryu KH, Jung K, Han CK, et al: Effects of SKI 306X, a new herbal agent, on proteoglycan degradation in cartilage explant culture and collagenase-induced rabbit osteoarthritis model. Osteoarthritis Cartilage. 2002, 10: 471-478. 10.1053/joca.2002.0526.PubMed
128.
Ryttig K, Schlamowitz PV, Warnoe O, Wilstrup F: [Gitadyl versus ibuprofen in patients with osteoarthrosis. The result of a double-blind, randomized cross-over study]. Ugeskr Laeger. 1991, 153: 2298-2299.PubMed
129.
Teekachunhatean S, Kunanusorn P, Rojanasthien N, Sananpanich K, Pojchamarnwiputh S, Lhieochaiphunt S, Pruksakorn S: Chinese herbal recipe versus diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial [ISRCTN70292892]. BMC Complement Altern Med. 2004, 4: 19-27. 10.1186/1472-6882-4-19.PubMedCentralPubMed
130.
Usha PR, Naidu MUR: Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clinical Drug Investigation. 2004, 24: 353-363. 10.2165/00044011-200424060-00005.PubMed
131.
Kim LS, Axelrod LJ, Howard P, Buratovich N, Waters RF: Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. Osteoarthritis Cartilage. 2006, 14: 286-294. 10.1016/j.joca.2005.10.003.PubMed
132.
Kacar C, Gilgil E, Tuncer T, Butun B, Urhan S, Sunbuloglu G, Yildirim C, Arikan V, Dundar U, Oksuz MC, et al: The association of milk consumption with the occurrence of symptomatic knee osteoarthritis. Clin Exp Rheumatol. 2004, 22: 473-476.PubMed
133.
Bijlsma JW: Milk consumption and osteoarthritis: a doubtful connection. Clin Exp Rheumatol. 2004, 22: 387-388.PubMed
134.
Colker CM, Swain M, Lynch L, Gingerich DA: Effects of a milk-based bioactive micronutrient beverage on pain symptoms and activity of adults with osteoarthritis: a double-blind, placebo-controlled clinical evaluation. Nutrition. 2002, 18: 388-392. 10.1016/S0899-9007(01)00800-0.PubMed
135.
Zenk JL, Helmer TR, Kuskowski MA: The effects of milk protein concentrate on the symptoms of osteoarthritis in adults: an exploratory, randomized, double-blind, placebo-controlled trial. Current Therapeutic research. 2002, 63: 430-442. 10.1016/S0011-393X(02)80049-2.
136.
Gingerich DA, Strobel JD: Use of client-specific outcome measures to assess treatment effects in geriatric, arthritic dogs: controlled clinical evaluation of a nutraceutical. Vet Ther. 2003, 4: 56-66.PubMed
137.
Moskowitz RW: Role of collagen hydrolysate in bone and joint disease. Semin Arthritis Rheum. 2000, 30: 87-99. 10.1053/sarh.2000.9622.PubMed
138.
Adam M: Therapy for osteoarthritis: which effects have preparations of gelatin?. Therapiewoche. 1991, 38: 2456-2461.
139.
Oesser S, Seifert J: Stimulation of type II collagen biosynthesis and secretion in bovine chondrocytes cultured with degraded collagen. Cell Tissue Res. 2003, 311: 393-399.PubMed
140.
Oesser S, Adam M, Babel W, Seifert J: Oral administration of (14)C labeled gelatin hydrolysate leads to an accumulation of radioactivity in cartilage of mice (C57/BL). J Nutr. 1999, 129: 1891-1895.PubMed
141.
Khan KS, ter Riet G, Popay J, Nixon J, Kleijnen J: Phase 5: study quality assessment in undertaking systematic reviews of research on effectiveness. Undertaking Systematic Reviews of Research on Effectiveness. CRD's Guidance for Those Carrying Out or Commissioning Reviews. Edited by: Khan KS, ter Riet G, Glanville J, Sowden AJ, Kleijnen J. 2001, York: York Publishing Services Ltd, 45-65.
142.
Singer F, Singer C, Oberleitner H: Phlogenzym versus diclofenac in the treatment of activated osteoarthritis of the knee. Int J Immunother. 2001, 17: 135-141.
Metadata
Title
Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence
Authors
Laurent G Ameye
Winnie SS Chee
Publication date
01-08-2006
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 4/2006
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2016

Other articles of this Issue 4/2006

Arthritis Research & Therapy 4/2006 Go to the issue

Research article

Impairment of chondrocyte biosynthetic activity by exposure to 3-tesla high-field magnetic resonance imaging is temporary

Research article

Autoimmune targeting of key components of RNA interference

Research article

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity

Research article

Mice expressing HLA-DQ6α8β transgenes develop polychondritis spontaneously

Research article

Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays

Research article

The MHC2TA-168A>G gene polymorphism is not associated with rheumatoid arthritis in Austrian patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits